Repair Biotechnologies, Inc.
June 18, 2025
Company Presentation
Cardiovascular
Repair Biotechnologies' platform technology enables rapid clearance of excess intracellular free cholesterol, an undruggable target that contributes to the pathology of many age-related and obesity-related conditions. The company's lead drug REP-0003 produces dramatic, rapid regression of arterial plaque in preclinical models of atherosclerosis and familial hypercholesterolemia, making it the first potentially curative therapy for atherosclerotic cardiovascular disease.
Company HQ City:
Syracuse
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
REP-0003, a LNP-mRNA drug that clears intracellular free cholesterol to regress atherosclerotic lesions.
CEO
Reason
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Large mammal data.
What is your next catalyst (value inflection) update?
08/2025.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}